Yifan Pharmaceutical Co., Ltd.
Symbol: 002019.SZ
SHZ
11.4
CNYMarktpreis heute
-33.8207
P/E-Verhältnis
0.4747
PEG-Verhältnis
13.89B
MRK Kapital
- 0.00%
DIV Rendite
Yifan Pharmaceutical Co., Ltd. (002019-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3477.57 | 773.4 | 1239.3 | 1336.1 | |||||||||||||||||||||||
balance-sheet.row.short-term-investments | 345.01 | 75 | 95.5 | -62.1 | |||||||||||||||||||||||
balance-sheet.row.net-receivables | 5608.97 | 1390.5 | 1527.3 | 1391 | |||||||||||||||||||||||
balance-sheet.row.inventory | 3879.32 | 928.6 | 831 | 663.9 | |||||||||||||||||||||||
balance-sheet.row.other-current-assets | 637.11 | 158.6 | 92.4 | 194.5 | |||||||||||||||||||||||
balance-sheet.row.total-current-assets | 13602.98 | 3251.1 | 3689.9 | 3585.5 | |||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 6805.25 | 1811.8 | 1601.4 | 1642.8 | |||||||||||||||||||||||
balance-sheet.row.goodwill | 10950.38 | 2737.4 | 2737.8 | 2737.8 | |||||||||||||||||||||||
balance-sheet.row.intangible-assets | 12107.43 | 2605.6 | 3298.7 | 3091.4 | |||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 23057.8 | 5343 | 6036.5 | 5829.2 | |||||||||||||||||||||||
balance-sheet.row.long-term-investments | 2619.46 | 718.5 | 601.2 | 702.2 | |||||||||||||||||||||||
balance-sheet.row.tax-assets | 1129.77 | 257.8 | 290.8 | 244.4 | |||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 992.6 | 117.4 | 323.7 | 161 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 34604.87 | 8248.4 | 8853.6 | 8579.6 | |||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.total-assets | 48207.85 | 11499.6 | 12543.5 | 12165.1 | |||||||||||||||||||||||
balance-sheet.row.account-payables | 1628.12 | 431.4 | 288.4 | 350.9 | |||||||||||||||||||||||
balance-sheet.row.short-term-debt | 4633.39 | 1116.4 | 1231.2 | 1438.9 | |||||||||||||||||||||||
balance-sheet.row.tax-payables | 219.64 | 19.1 | 107.5 | 82.6 | |||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 3295.67 | 812 | 930.9 | 820.3 | |||||||||||||||||||||||
Deferred Revenue Non Current | 397.93 | 99.7 | 104.8 | 85.7 | |||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 383.83 | - | - | - | |||||||||||||||||||||||
balance-sheet.row.other-current-liab | 1089.05 | 506.4 | 476.5 | 7.5 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 4200.61 | 957.6 | 1197.9 | 1088.7 | |||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 269.78 | 66.7 | 80.7 | 89.8 | |||||||||||||||||||||||
balance-sheet.row.total-liab | 12952.29 | 3144.9 | 3397.3 | 3390.6 | |||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.common-stock | 4185.27 | 1046.3 | 1046.3 | 1054.4 | |||||||||||||||||||||||
balance-sheet.row.retained-earnings | 18318.97 | 4204.1 | 4754.6 | 4562.1 | |||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 6739.51 | 200.9 | 27.2 | 76.4 | |||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5406.71 | 2824.4 | 2983.4 | 2842.3 | |||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 34650.46 | 8275.6 | 8811.5 | 8535.2 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 48207.85 | 11499.6 | 12543.5 | 12165.1 | |||||||||||||||||||||||
balance-sheet.row.minority-interest | 505.36 | -20.7 | 334.8 | 239.4 | |||||||||||||||||||||||
balance-sheet.row.total-equity | 35155.81 | 8254.9 | 9146.2 | 8774.6 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 48207.85 | - | - | - | |||||||||||||||||||||||
Total Investments | 2964.47 | 793.5 | 696.7 | 640.1 | |||||||||||||||||||||||
balance-sheet.row.total-debt | 8055.08 | 1995.2 | 2162.1 | 2259.2 | |||||||||||||||||||||||
balance-sheet.row.net-debt | 4922.52 | 1296.8 | 1018.3 | 923.1 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -469.75 | 127.2 | 242.2 | 931.4 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 18.71 | 228.4 | 207.2 | 177 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -53.9 | -87 | -33.4 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 53.9 | -7 | 82.8 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | -97.84 | -168.2 | -285.4 | -178.5 | ||||||||||||||||||||
cash-flows.row.account-receivables | -10.25 | -103.8 | -18.6 | -117.7 | ||||||||||||||||||||
cash-flows.row.inventory | -109.39 | -167.1 | -80.5 | 21.9 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 156.6 | -99.3 | -49.2 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 21.79 | -53.9 | -87 | -33.4 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 1043.98 | 284.7 | 231.3 | 129.2 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 495.1 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -516.29 | -542.3 | -571.7 | -715.7 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 11.1 | 1.2 | -26.1 | -36.8 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | -1437.41 | -1253.6 | -1265 | -1141 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1404.08 | 1118 | 1337.2 | 1122 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | -349.06 | 6.5 | 17.7 | 1 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -538.51 | -670.2 | -507.9 | -770.6 | ||||||||||||||||||||
cash-flows.row.debt-repayment | -754.5 | -1880.3 | -2432.7 | -2210 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.8 | 1 | 1.6 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | -38 | -53.6 | -121.5 | -1.6 | ||||||||||||||||||||
cash-flows.row.dividends-paid | -68.79 | -86.4 | -138.4 | -202 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 569.44 | 2006.7 | 2913.7 | 1844 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -78.12 | -12.7 | 222.2 | -567.9 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 16.15 | 59.6 | -20.9 | 1.3 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | -45.08 | -151.2 | -5.4 | -228.7 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 3004.74 | 711.6 | 862.8 | 868.2 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 3049.83 | 862.8 | 868.2 | 1096.8 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 495.1 | 472.1 | 301.2 | 1108.5 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | -516.29 | -542.3 | -571.7 | -715.7 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | -21.2 | -70.2 | -270.5 | 392.8 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 4433.29 | 4022.2 | 3836.6 | 4409 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 2354.45 | 2191.3 | 1970.7 | 2580.7 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | 2078.84 | 1830.9 | 1865.9 | 1828.4 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 320.03 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 115.55 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1184.2 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | -859.52 | -26.3 | 161.9 | 248.2 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 2783.92 | 1821.4 | 1525 | 1476.3 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 5138.37 | 4012.7 | 3495.7 | 4057 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 16.25 | 13.1 | 21.4 | 25.3 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 71.66 | 75.6 | 85.8 | 74.6 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1184.2 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 55.19 | -859.2 | -242.6 | -137.8 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -859.52 | -26.3 | 161.9 | 248.2 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 55.19 | -859.2 | -242.6 | -137.8 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 71.66 | 75.6 | 85.8 | 74.6 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 248.89 | 279.8 | 228.4 | 207.2 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | -554.16 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | -800.46 | 9.5 | 399.4 | 348.6 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | -745.27 | -849.8 | 156.7 | 210.8 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 56.73 | 16.6 | 29.6 | -31.4 | |||||||||||||||||||||||
income-statement-row.row.net-income | -469.75 | -551.1 | 127.2 | 278.4 |
Häufig gestellte Frage
Wie hoch ist die Yifan Pharmaceutical Co., Ltd. (002019.SZ) Gesamtvermögen?
Yifan Pharmaceutical Co., Ltd. (002019.SZ) Gesamtvermögen ist 11499585782.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 2441543691.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.469.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.017.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -0.106.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.181.
Was ist der Yifan Pharmaceutical Co., Ltd. (002019.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -551073063.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 1995190642.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 1821437913.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 810555981.000.